Core Viewpoint - The appointment of Dr. Yi Xiao as Executive Director and Chief Scientist at Huajian Medical is seen as a pivotal move to revitalize the company's stock performance and investor confidence amidst a challenging market environment [2][3]. Group 1: Strategic Shift - Huajian Medical is adopting an innovative "reverse NewCo" model to navigate high valuations and regulatory barriers in the global AI medical landscape, focusing on equity partnerships rather than direct acquisitions [4]. - The company plans to leverage its extensive distribution network of over 1,700 tier-three hospitals and a vast repository of health data from its acquisition of Chuangye Huikang to attract global partners with advanced AI technologies [4][5]. Group 2: Advantages of the New Model - The "reverse NewCo" model minimizes capital expenditure and regulatory risks associated with direct acquisitions, enhancing capital efficiency and compliance [5]. - Huajian Medical positions itself as a core creator and amplifier of technology value in the Chinese market, sharing in the exponential commercialization of technologies through its ecosystem [5]. - The model allows for rapid market entry of overseas technologies, facilitating immediate synergies within Huajian's ecosystem [5]. Group 3: Dr. Yi Xiao's Role - Dr. Yi Xiao's expertise in cutting-edge research and clinical translation is crucial for Huajian Medical's ability to evaluate and implement global AI medical technologies effectively [6][9]. - Her team has developed innovative cervical cancer organoid models and extracellular matrix bio-nanomaterials, showcasing strong academic and practical capabilities [7][8]. Group 4: Enhancing Collaboration and Data Utilization - Dr. Yi Xiao will enhance the technical assessment and localization of technologies within the "reverse NewCo" framework, ensuring that overseas innovations are tailored for the Chinese market [11]. - The integration of Chuangye Huikang's extensive medical data with Dr. Yi's research will drive data-driven development and AI applications, creating new business models for Huajian Medical [12]. Group 5: Addressing Market Concerns - Recent developments, including Dr. Yi's appointment, are addressing previous market skepticism regarding Huajian Medical's growth and technological foundation in AI healthcare [14]. - The company is enhancing its asset identification capabilities by combining financial and technical due diligence to ensure the acquisition of hard technology assets [14]. - Stock buybacks totaling over HKD 100 million since 2025 reflect management's confidence in the company's intrinsic value and commitment to shareholder interests [14]. Group 6: Future Outlook - Huajian Medical is strategically positioned at the intersection of significant trends in AI and multi-omics, aiming to create a comprehensive AI medical ecosystem that integrates data, algorithms, materials, clinical applications, and distribution channels [15].

Core Viewpoint - The appointment of Dr. Yi Xiao as Executive Director and Chief Scientist at Huajian Medical is seen as a pivotal move to revitalize the company's stock performance and investor confidence amidst ongoing challenges in the AI medical sector [4]. Group 1: Company Strategy - Huajian Medical is adopting an innovative "reverse NewCo" model to navigate high valuations and regulatory barriers in the global AI medical landscape, focusing on equity partnerships rather than direct acquisitions [5]. - The company plans to leverage its extensive distribution network of over 1,700 tier-three hospitals in China and a vast repository of health data from its acquisition of Chuangye Huikang to attract global partners with advanced AI technologies [5][6]. - This model aims to enhance capital efficiency and compliance while allowing Huajian Medical to become a core creator and magnifier of technology value in the Chinese market [6]. Group 2: Dr. Yi Xiao's Contributions - Dr. Yi Xiao brings exceptional academic credentials and research capabilities, having published groundbreaking work in the field of organoids and extracellular matrix materials in top-tier journals [8]. - Her team has developed a novel cervical cancer organoid model and a foundational material for regenerative medicine, which has received significant recognition and regulatory approval [9]. - Dr. Yi's expertise will enable Huajian Medical to effectively evaluate and integrate global AI medical technologies, ensuring successful market entry in China [10]. Group 3: Synergy and Collaboration - Dr. Yi will play a crucial role in enhancing the "reverse NewCo" model by conducting thorough scientific validations of potential technologies and guiding their localization for the Chinese market [12]. - The collaboration with Chuangye Huikang will allow for the integration of vast medical data into research and development, facilitating the creation of AI-driven solutions for precision medicine [13]. - This partnership aims to transition Huajian Medical from a traditional reagent sales model to a service-oriented approach, providing comprehensive diagnostic solutions [13]. Group 4: Market Perception and Future Outlook - Recent developments, including Dr. Yi's appointment, are addressing market skepticism regarding Huajian Medical's growth potential and the substantiation of its AI medical narrative [15]. - The company is enhancing its asset identification capabilities by combining financial and technical due diligence to ensure the acquisition of hard technology assets [15]. - Huajian Medical's strategic initiatives position it to capitalize on the growing trend of AI integration in healthcare, with projections indicating significant growth in AI medical spending [16].